What is INSP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for INSP?

P/E (TTM) is 14.77 and 52-week range is $38.91 to $147.03 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s INSP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for INSP?

The company profile lists revenue (TTM) near $895M, net income (TTM) near $134M, EPS (TTM) near $4.61 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Inspire Medical Systems Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Golden Valley, Minnesota, US, 28.8M shares outstanding, ISIN US4577301090 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Inspire Medical Systems Inc

$INSP

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$68.79

-1.90%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Inspire Medical Systems, Inc. is a medical technology company, which focuses on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The company is headquartered in Golden Valley, Minnesota and currently employs 1,333 full-time employees. The company went IPO on 2018-05-03. The firm focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The firm's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The firm sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.

Employees

1,333

Website

www.inspiresleep.com/

IPO

2018-05-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)